Diclofenac gel
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Superficial Thrombophlebitis of the Upper Limb
Conditions
Superficial Thrombophlebitis of the Upper Limb
Trial Timeline
Jan 1, 2003 → Sep 1, 2006
NCT ID
NCT00377806About Diclofenac gel
Diclofenac gel is a approved stage product being developed by Novartis for Superficial Thrombophlebitis of the Upper Limb. The current trial status is completed. This product is registered under clinical trial identifier NCT00377806. Target conditions include Superficial Thrombophlebitis of the Upper Limb.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00377806 | Approved | Completed |
Competing Products
11 competing products in Superficial Thrombophlebitis of the Upper Limb
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EG-70 (phase 1) + EG-70 (phase 2) | enGene | Phase 1/2 | 33 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + mitomycin C | Eli Lilly | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Dalteparin sodium injection | Pfizer | Approved | 84 |
| Rivaroxaban + Fondaparinux | Bayer | Phase 3 | 74 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Chemophase | Halozyme Therapeutics | Phase 1 | 30 |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Relmada Therapeutics | Phase 3 | 69 |
| EscharEx 5% (EX-02 formulation) | MediWound | Phase 1/2 | 33 |